Following European approval in 2011, Second Sight Medical Products, Inc. received U.S. market approval from the Food and Drug Administration (FDA) to treat individuals with late stage retinitis pigmentosa (RP) with its Argus® II Retinal Prosthesis System (“Argus II”). The Argus II restores some functional vision for people suffering from blindness using a combination of an implant and external equipment.
Surgically implanted in and on the eye, the epiretinal prosthesis (implant) includes an antenna, an electronics case, and a 60-pixel electrode array. The external equipment includes glasses with an antenna, a video processing unit (VPU) and a cable .The charge-coupled display (CCD) sensor produces a 20° maximum possible field of view.
For more information about the Argus II Retinal Prosthesis System including a video of the system in action, click here.